Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
biomodal logo — Reveal the power of the 6-base genome and discover biology i...

biomodal

Reveal the power of the 6-base genome and discover biology in every mode

Founded 2012 United Kingdom Cambridge, United Kingdom 87 employees Venture round Biotechnology, Health Care +1

General Information

Company Name biomodal
Founded Year 2012
Location United Kingdom Cambridge, United Kingdom
Employees 87
Industries Biotechnology, Health Care, Life Sciences
Funding Stage Venture round
Business Model B2B, SaaS, Platform
Revenue Model Product Sales, Usage Based, Licensing
Offices as of Sep 2026
Cambridge, United Kingdom London, United Kingdom
Social

BounceWatch is an independent company data service, not affiliated with biomodal. To contact biomodal, visit biomodal.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does biomodal compare?

A PDF of biomodal and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting biomodal soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About biomodal

biomodal, founded in 2012, is a pioneering company at the forefront of biotech innovation. Specializing in omics-based life sciences technology and analytics, biomodal is known for its duet multiomics solutions that enhance epigenetic data acquisition from minimal DNA samples. This approach allows for unparalleled insight into complex biological systems with applications spanning cancer, neurodegenerative diseases, and ageing.

The company, headquartered in the United Kingdom, has gained significant industry recognition, notably being listed in "The Sunday Times 100 Tech 2026." Biomodal's innovative sequencing technologies unlock the synergies between genetic and epigenetic data, offering groundbreaking potential for advancements in biotechnology and health care.

Despite its last documented investment being a Venture Round in January 2015, led by Sequoia Capital Global Equities, biomodal continues to attract attention for its capacity to advance life sciences through its transformative products and technologies.

Business keywords: 6-base genome, multiomics solutions, epigenetics, single-base-resolution sequencing, cancer research, neurodegenerative disease, ageing research, genetic information analysis, epigenetic information, biomarker discovery, diagnostic assays, precision medicine, low input DNA analysis, genetic and epigenetic combinatorial insights, life sciences technology

Services & Products

duet multiomics solution evoC
duet multiomics solution +modC
custom multiomic solutions
modality XPLR for explorative research
integrated genetic and epigenetic sequencing

Target Customers

research institutions biotech companies healthcare providers clinical researchers pharmaceutical companies

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round Undisclosed 1
Sequoia Capital Global Equities
01 Jan 2015

biomodal Alternatives & Competitors

View All Alternatives
biomodal vs
Cambridge Epigenetix
Cambridge Epigenetix

Innovating healthcare with a simple blood test for early detection of colorectal cancer and other tu...

Series D
51-200 employees
Biotechnology, Health Care
biomodal vs
JMDNA
JMDNA

JMDNA was founded in 2012 and headquartered in Shanghai, China. It is dedicated to providing the bes...

Series B
20 employees
Biotechnology, Health Care
biomodal vs
Helicos Biosciences Corporation
Helicos Biosciences Corporation United States

The Helicos® Genetic Analysis System is the first technology capable of true direct RNA, cDNA and DN...

Series A
8 employees
Biotechnology, Health Care
View all alternatives

FAQ About biomodal

Reveal the power of the 6-base genome and discover biology in every mode
biomodal was founded in 2012.
biomodal is headquartered in Cambridge, United Kingdom. As of Sep 2026, it also has offices in London, United Kingdom.
biomodal operates in Biotechnology, Health Care and Life Sciences. Its work centres on 6-base genome, multiomics solutions, epigenetics and single-base-resolution sequencing. Its customers include research institutions, biotech companies and healthcare providers.
biomodal has a B2B, SaaS and Platform business model. Its revenue comes from Product Sales, Usage Based and Licensing.
biomodal has approximately 87 employees.
biomodal has completed 1 funding round. The latest funding stage is Venture round.
biomodal offers: duet multiomics solution evoC, duet multiomics solution +modC, custom multiomic solutions, modality XPLR for explorative research, integrated genetic and epigenetic sequencing.
Top alternatives and competitors to biomodal include Cambridge Epigenetix, JMDNA, Helicos Biosciences Corporation, MNM Bioscience, Atrandi Biosciences. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
biomodal and Cambridge Epigenetix are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for biomodal, https://bouncewatch.com/company/biomodal, updated 26 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes